Abstract
DLYE5953A is an antibody-drug conjugate consisting of an anti-LY6E antibody covalently linked to the cytotoxic agent monomethyl auristatin E. This study characterized the safety, pharmacokinetics, immunogenicity, potential biomarkers, and anti-tumor activity of DLYE5953A in patients with metastatic solid tumors. This was a phase I, open-label, 3+3 dose-escalation, and dose expansion study of DLYE5953A administered intravenously every 21 days (Q3W) in patients with locally advanced or metastatic solid malignancies. Sixty-eight patients received DLYE5953A (median: 4 cycles; range: 1-27). No dose limiting toxicities were identified during dose escalation (0.2-2.4 mg/kg; n=20). The recommended phase II dose (RP2D) of 2.4 mg/kg Q3W was based on overall safety and tolerability. Dose expansion cohorts for HER2-negative metastatic breast cancer (HER2-negative MBC) (n=23) and non-small cell lung cancer (NSCLC) (n=25) patients were enrolled at the RP2D. Among patients receiving DLYE5953A 2.4 mg/kg (n=55), the most common (>=30%) related adverse events (AEs) included alopecia, fatigue, nausea, and peripheral neuropathy. Grade >=3 related AEs occurred in 14/55 (26%) of patients, with neutropenia being the most common (13%). DLYE5953A demon...Continue Reading
References
Jun 20, 1998·The Journal of Biological Chemistry·A KosugiT Hamaoka
Sep 11, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·R Angelo de ClaroRichard Pazdur
Sep 17, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Xuan XuJianqing Xu
Nov 29, 2014·Journal of Medicinal Chemistry·Andreas MadernaChristopher J O'Donnell
Apr 5, 2015·Molecular Cancer Therapeutics·Robert ChenSusan E Kane
Apr 5, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shang-Fan YuAndrew G Polson
Apr 12, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jyoti AsundiRon Firestein
Jan 30, 2016·Molecular Cancer Therapeutics·Colin D WeekesGerardo Colon-Otero
May 20, 2016·Cancer Research·Midrar AlHossinyGeeta Upadhyay
Oct 30, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J F LiuH A Burris
Sep 18, 2017·Journal of Pharmacokinetics and Pharmacodynamics·Matts KågedalChunze Li
Apr 28, 2015·Toxics·Roser Velasco, Jordi Bruna
Sep 8, 2018·Nature Communications·Katrina B MarJohn W Schoggins
Oct 18, 2018·Cell Reports·Simon JoostMaria Kasper
Jun 19, 2019·Bioanalysis·Montserrat Carrasco-TrigueroSurinder Kaur
Sep 22, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David E GerberHoward A Burris
Nov 7, 2019·Viruses·Jingyou Yu, Shan-Lu Liu
Nov 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel C DanilaHoward I Scher